Tag: site specific conjugation
Advances in the Development of Dual-Drug Antibody Drug Conjugates
Antibody drug conjugates (ADCs) are touted for their ability to site selectively deliver a small molecule chemotherapeutic directly to a tumor cell, bypassing off target side effects from systemic circulation. To date, eleven ADCs have been FDA approved in the United States and >200 more in the clinical pipeline (clinicaltrials.gov).
CStone Pharmaceuticals and LegoChem Biosciences Enter Global Licensing Agreement for...
Suzhou (China-) based CStone Pharmaceuticals and LegoChem Biosciences have signed a global licensing agreement in which CStone acquires exclusive rights for development and commercialization...
NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple...
Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for applications within oncology and hematology....
PEGS: Novel Technology to Enhance Cell Line Productivity and Expand the...
During the 16th Annual PEGS Boston Virtual Conference & Expo, which took place between August 31 – September 4, 2020, Gregory Bleck, Ph.D., Global...
BrickBio’s Novel Therapeutic Conjugation Platform Validated at Commercial Scale
Boston-based BrickBio has demonstrated its ability to insert unnatural amino acids (UAAs; called "attachment bricks"), at any site, specifically, within a protein or antibody...
Trio Pharmaceuticals and Ajinomoto Ink Agreement to Develop First-in-class Dual Functionality...
Patients being treated for cancer may often benefit from a combination of systemic cancer chemotherapies. The rationale for the combination of multiple anti-cancer therapies...
Addressing the Challenges of Bioconjugate Medicines
Abstract
The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-, radionuclide-, immunomodulator- and check-point inhibitor-conjugates, can start to address the...
New ADC Payload Platform – Synaffix Launches toxSYN™
The Netherlands-based biotech company Synaffix, which has developed a proprietary site-specific conjugation platform technology to enable differentiated antibody-drug conjugates or ADCs, launched of a...
PEGG 2017: RESPECT Antibody-drug Conjugate Technology
Earlier this year, a record number of 2,300 delegates attended the 13th edition of the "PEGS: The Essential Protein Engineering Summit," held May 1...
Selenomab-drug Conjugates: Delivering Strong Results in Treating Cancers
Scientists from the Florida campus of The Scripps Research Institute (TSRI), one of the world's largest independent, not-for-profit organizations focusing on research in the...
